ArticleInvestigational new drugs2002

Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice.

Lisa Polin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.